Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of LY3039478 in Patients With Advanced or Metastatic Cancer

Trial Profile

A Phase 1 Study of LY3039478 in Patients With Advanced or Metastatic Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crenigacestat (Primary)
  • Indications Adenoid cystic carcinoma; B-cell lymphoma; Breast cancer; Cholangiocarcinoma; Chronic lymphocytic leukaemia; Gastrointestinal stromal tumours; Leiomyosarcoma; Liver cancer; Lymphoma; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 06 Apr 2019 Results (n=22) of expansion cohort of patients with advanced or metastatic adenoid cystic carcinoma published in the Investigational New Drugs
    • 12 Sep 2018 Results published in the European Journal of Cancer.
    • 06 Aug 2018 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top